alexa Budget Impact Analysis of Tofacitinib for treatment of Rheumatoid Arthritis
ISSN: 2167-7921

Journal of Arthritis
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Budget Impact Analysis of Tofacitinib for treatment of Rheumatoid Arthritis

Rituparna Bhattacharya1* and Khalid M. Kamal2
1Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, West Virginia
2Mylan School of Pharmacy, Clinical, Social and Administrative Sciences, Pittsburg, Pennsylvania, USA
Corresponding Author : Rituparna Bhattacharya
MS, Department of Pharmaceutical Systems and Policy
School of Pharmacy, West Virginia University, Morgantown, West Virginia
Tel: (304)293.2968
E-mail: [email protected]
Received January 23, 2015; Accepted April 28, 2015; Published May 07, 2015
Citation: Bhattacharya R, Kamal KM (2015) Budget Impact Analysis of Tofacitinib for treatment of Rheumatoid Arthritis. J Arthritis 4:152. doi:10.4172/2167-7921.1000152
Copyright: © 2015 Bhattacharya R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 

Abstract

Objective: Tofacitinib is a novel oral biologic that has been approved for treating adults with Rheumatoid arthritis (RA) having inadequate response to or are intolerant of methotrexate (MTX). The objective of this study was to conduct a budget impact model (BIM) analysis for estimating direct annual drug costs for individuals with RA before and after the introduction tofacitinib as a formulary option. Research Design and Methods: The BIM was developed using a US healthcare payer?s perspective with a one-year time frame. The tumor necrosis factor inhibitors (anti-TNFs) adalimumab, etanercept, infliximab, golimumab and certolizumab were considered as comparators. The BIM tested two base-case scenarios: ?Base-case scenario 1: Incident anti-TNF users?; ?Base-case scenario 2: Prevalent anti-TNF users?. Both the scenarios were evaluated under the following two conditions: (1) assuming monotherapy except for infliximab and golimumab and (2) assuming combination therapy with MTX. One way sensitivity analyses were conducted to test the uncertainty in model parameters. Main Outcome Measures: Per member per month cost. Results: Under scenario 1, the decrease in total annual budget for the revised formulary was expected to be $449,769 or $0.04 per member per month (PMPM). With combination therapy, the over-all budget decrease was $43,482 or $0.004 PMPM. For scenario 2, the total annual budget savings with the revised formulary was expected to be $1,536,712 or $ 0.13 PMPM and $ 148,564 or $ 0.012 PMPM for mono and combination therapy, respectively. One-way sensitivity analysis revealed that results were sensitive to adherence rates of anti-TNFs and tofacitinib. Conclusion: Given the easier route of administration and minimal impact on budget of health plans, tofacitinib can be considered as a viable treatment option for individuals with Rheumatoid Arthritis.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords